Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11779578 IRAK degraders and uses thereof

Patent 11779578 was granted and assigned to Kymera Therapeutics on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

Kymera Therapeutics

Current Assignee

Kymera Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Matthew M. Weiss

Date of Patent

October 10, 2023

Patent Application Number

17125426

Date Filed

December 17, 2020

Patent Citations

US Patent 7402325 Supercritical carbon dioxide extract of pharmacologically active components from

US Patent 7449458 Prodrugs of 2,4-pyrimidinediamine compounds and their uses

US Patent 7501496 Anti-OX40L antibodies

US Patent 7514444 Inhibitors of bruton's tyrosine kinase

US Patent 7528143 Bi-aryl meta-pyrimidine inhibitors of kinases

US Patent 7557210 2,4-pyrimidinediamine compounds and their uses

US Patent 7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors

US Patent 7622496 Modified lysine-mimetic compounds

...

Patent Primary Examiner

Zinna Northington Davis

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11779578 IRAK degraders and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool